Belite Bio Inc American Depositary Shares (BLTE)
Stock · NASDAQ · Health Care
$151.72as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$153.23
Industry
Biotechnology: Pharmaceutical Preparations
About BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geog…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 41
- Website
- belitebio.com/
Fundamentals
- 1-day range
- $151.15$156.75
- Market cap
- $6.09B
- P/E (trailing)
- —
- P/E (forward)
- 70.85
- EPS (trailing)
- $-2.65
- Dividend yield
- —
- Beta
- -1.22
- Avg. volume
- 198.1K
52-week range
$62.18$200
Next earnings: November 9, 2026 · EPS estimate $-0.78confirmed
Forecasts
8 analyst ratings
Buy 93%
Hold 7%
Sell 0%
1-year price forecast
High
$270
+78.0%
Median
$210
+38.4%
Low
$185
+21.9%
Belite Bio Inc American Depositary Shares Competitors
Chosen by industry and closest market cap.
- BLTEBelite Bio Inc American Depositary Shares$151.65▼ 3.42%Market cap $6.09BP/E —$62.18$200
- ERASErasca Inc. Common Stock$18.03▼ 7.49%Market cap $6.11BP/E —$1.33$24.28
- LGNDLigand Pharmaceuticals Incorporated Common Stock$280▼ 1.59%Market cap $5.85BP/E 38.07$158.4$326.63
- MIRMMirum Pharmaceuticals Inc. Common Stock$97.44▼ 2.32%Market cap $6.38BP/E —$63.23$130
- DNTHDianthus Therapeutics Inc. Common Stock$105.72▼ 5.22%Market cap $5.80BP/E —$22.81$117.88
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.1▼ 2.13%Market cap $5.73BP/E 75.29$33.25$82.94
- PTCTPTC Therapeutics Inc. Common Stock$70.01▼ 2.51%Market cap $5.68BP/E —$48.86$90.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BLTE Belite Bio Inc American Depositary Shares | $6.09B | — | $151.65 | ▼ 3.42% | $62.18$200 |
| ERAS Erasca Inc. Common Stock | $6.11B | — | $18.03 | ▼ 7.49% | $1.33$24.28 |
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $5.85B | 38.07 | $280 | ▼ 1.59% | $158.4$326.63 |
| MIRM Mirum Pharmaceuticals Inc. Common Stock | $6.38B | — | $97.44 | ▼ 2.32% | $63.23$130 |
| DNTH Dianthus Therapeutics Inc. Common Stock | $5.80B | — | $105.72 | ▼ 5.22% | $22.81$117.88 |
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.73B | 75.29 | $78.1 | ▼ 2.13% | $33.25$82.94 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.68B | — | $70.01 | ▼ 2.51% | $48.86$90.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206Benzinga · 8/14/2026
- Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270Benzinga · 8/14/2026
- Belite Bio, Inc (BLTE) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/13/2026
- Full Transcript: Belite Bio Q2 2026 Earnings CallBenzinga · 8/13/2026
- Belite Bio Q2 Adj. EPS $(0.54) Beats $(0.79) EstimateBenzinga · 8/13/2026
- CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga · 8/12/2026
- HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $214Benzinga · 8/12/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
11.8K
- Hao-Yuan Chuang · August 12, 2026 · Sale223 @ $180.57
- Hao-Yuan Chuang · August 12, 2026 · Sale144 @ $180
- Yu-Hsin Lin · August 12, 2026 · Sale223 @ $180.57
- Yu-Hsin Lin · August 12, 2026 · Sale142 @ $180
- Hendrik Peter Scholl · June 18, 2026 · Sale96 @ $143.9
- Hendrik Peter Scholl · June 18, 2026 · Sale1.2K @ $146.24
- Hendrik Peter Scholl · June 18, 2026 · Sale4.9K @ $145.43
- Hendrik Peter Scholl · June 18, 2026 · Sale3.7K @ $144.66
- Nathan L. Mata · May 7, 2026 · Sale9 @ $155.25
- Nathan L. Mata · May 7, 2026 · Sale3 @ $154.61
- Nathan L. Mata · May 7, 2026 · Sale428 @ $153.56
- Nathan L. Mata · May 7, 2026 · Sale226 @ $152.45
- Nathan L. Mata · May 6, 2026 · Sale100 @ $155.97
- Nathan L. Mata · May 6, 2026 · Sale240 @ $154.41
- Nathan L. Mata · May 6, 2026 · Sale128 @ $153.42
Institutional Ownership
March 31, 2026
- Total shares held
- 9.12M
- Total value held
- $1.36B
- Institutional holders
- 74
Top holders this quarter
- Unknown3.06M
- Unknown1.11M
- Unknown768.4K
- Unknown715.3K
- Unknown570.1K
- Unknown494.5K
- Unknown357.6K
- Unknown304.0K
- Unknown281.8K
- Unknown201.4K
See the full, filterable feed with live charts on the MarketWall dashboard.